Bliss GVS Pharma Limited
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessarie… Read more
Bliss GVS Pharma Limited (BLISSGVS) - Total Assets
Latest total assets as of September 2025: ₹14.00 Billion INR
Based on the latest financial reports, Bliss GVS Pharma Limited (BLISSGVS) holds total assets worth ₹14.00 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bliss GVS Pharma Limited - Total Assets Trend (2005–2025)
This chart illustrates how Bliss GVS Pharma Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bliss GVS Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Bliss GVS Pharma Limited's total assets of ₹14.00 Billion consist of 63.5% current assets and 36.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹132.61 Million | 1.8% |
| Accounts Receivable | ₹4.47 Billion | 34.4% |
| Inventory | ₹1.26 Billion | 9.7% |
| Property, Plant & Equipment | ₹4.18 Billion | 32.1% |
| Intangible Assets | ₹2.30 Million | 0.0% |
| Goodwill | ₹77.11 Million | 0.6% |
Asset Composition Trend (2005–2025)
This chart illustrates how Bliss GVS Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bliss GVS Pharma Limited's current assets represent 63.5% of total assets in 2025, a decrease from 75.0% in 2005.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2025, down from 3.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 34.4% of total assets.
Bliss GVS Pharma Limited Competitors by Total Assets
Key competitors of Bliss GVS Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Bliss GVS Pharma Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bliss GVS Pharma Limited generates 0.62x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Bliss GVS Pharma Limited generates $6.48 in net profit.
Bliss GVS Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.46 | 4.42 | 3.19 |
| Quick Ratio | 3.86 | 3.74 | 2.83 |
| Cash Ratio | 0.98 | 1.14 | 0.00 |
| Working Capital | ₹6.90 Billion | ₹ 6.59 Billion | ₹ 5.23 Billion |
Bliss GVS Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Bliss GVS Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 7.2% |
| Total Assets | ₹13.01 Billion |
| Market Capitalization | $103.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bliss GVS Pharma Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bliss GVS Pharma Limited's assets grew by 7.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bliss GVS Pharma Limited (2005–2025)
The table below shows the annual total assets of Bliss GVS Pharma Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹13.01 Billion | +7.16% |
| 2024-03-31 | ₹12.14 Billion | +4.93% |
| 2023-03-31 | ₹11.57 Billion | +4.34% |
| 2022-03-31 | ₹11.09 Billion | +2.97% |
| 2021-03-31 | ₹10.77 Billion | +4.64% |
| 2020-03-31 | ₹10.29 Billion | +13.72% |
| 2019-03-31 | ₹9.05 Billion | +5.21% |
| 2018-03-31 | ₹8.60 Billion | -12.78% |
| 2017-03-31 | ₹9.86 Billion | +29.44% |
| 2016-03-31 | ₹7.62 Billion | +15.04% |
| 2015-03-31 | ₹6.62 Billion | +13.62% |
| 2014-03-31 | ₹5.83 Billion | -0.40% |
| 2013-03-31 | ₹5.85 Billion | +88.90% |
| 2012-03-31 | ₹3.10 Billion | +45.08% |
| 2011-03-31 | ₹2.13 Billion | +34.26% |
| 2010-03-31 | ₹1.59 Billion | +25.31% |
| 2009-03-31 | ₹1.27 Billion | +39.80% |
| 2008-03-31 | ₹907.68 Million | +57.63% |
| 2007-03-31 | ₹575.84 Million | +612.78% |
| 2006-03-31 | ₹80.79 Million | +35.21% |
| 2005-03-31 | ₹59.75 Million | -- |